Axol Bioscience is a Cambridge- and Edinburgh-based life-sciences company that develops and supplies high-quality functional iPSC-derived cells, reagents and specialist services to pharmaceutical, biotech, CRO and academic customers worldwide. Its portfolio features physiologically relevant disease models for neurodegenerative disorders such as Huntington’s disease and sporadic ALS/MND, and the firm plans to broaden offerings into ophthalmology and cardiovascular research. Regulators’ push toward human-relevant in-vitro models has strengthened Axol’s market position. The company reported 36% revenue growth in 2024 and 45% in 2025, reflecting mounting global demand. Proceeds from the latest raise will expand U.S. operations, boost commercial reach and scale manufacturing at the Roslin Innovation Centre. Future product development will center on enhanced neuroscience, ophthalmology and cardiovascular models, supported by continued investment in quality systems. Axol has also deepened relationships with global pharmaceutical partners, underscoring its commercial momentum.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2026